PDE5A and COVID-19: In addition to offering protection against metabolic and cardiovascular diseases, these PDE5 inhibitors were predicted to be associated with the management of COVID-19 by impeding angiotensin-II-driven downregulation of AT-2 receptors, which induced monocyte switching to alleviate cytokine storm, interstitial infiltration, and blood vessel damage [34].